Zenas BioPharma Announces Investor Conference Presentations
Zenas BioPharma, Inc. (NASDAQ: ZBIO), a pioneering biopharmaceutical company, has revealed an impressive lineup of presentations at several upcoming investor conferences. These events represent a significant opportunity for the company to showcase its groundbreaking work in developing therapies aimed at treating autoimmune diseases.
Upcoming Investor Conferences
Management at Zenas BioPharma is set to present at the following notable conferences:
1. Jefferies Global Healthcare Conference
This event is scheduled for November 18 at 11:00 a.m. GMT in London, where the company plans to discuss its innovative product pipelines and potential impact on patient care.
2. 8th Annual Evercore Healthcare Conference
On December 3 at 7:55 a.m. ET, Zenas will participate in this conference, providing insights into their latest advancements and future strategies for growth.
Live Webcasts Available
For those interested in Zenas' presentations, live webcasts and archived replays will be accessible under 'Events and Presentations' on their website. This is a great chance for investors and stakeholders to hear directly from the management team about their vision and ongoing projects.
About Zenas BioPharma
Zenas BioPharma is dedicated to transforming the treatment landscape for patients suffering from autoimmune conditions. The company prides itself on its strategic approach to developing therapies that offer real clinical benefits. Their approach is underpinned by a knowledgeable leadership team and a dedicated effort to identify and develop groundbreaking product candidates.
Key Product Candidates
Zenas is actively advancing two late-stage molecules, obexelimab and orelabrutinib. Obexelimab stands out as the leading candidate, designed to target CD19 and Fc?RIIb, which are critical players in the immune response. This innovative therapeutic approach aims to modulate the activity of B cells implicated in autoimmune diseases without causing cell depletion. Such a method could revolutionize treatment approaches for chronic autoimmune diseases.
Orelabrutinib's Unique Benefits
Orelabrutinib is an oral small molecule BTK inhibitor known for its selectivity and ability to penetrate the central nervous system (CNS). Its dual-targeting mechanism not only affects peripheral pathogenic B cells but also influences CNS inflammation, making it a potentially transformative solution for conditions like Multiple Sclerosis (MS).
Early-Stage Programs and Innovations
Beyond their flagship products, Zenas is also pursuing early-stage development of additional candidates, including an oral IL-17AA/AF inhibitor and a TYK2 inhibitor capable of penetrating the brain. These promising therapies show great potential to enhance patient outcomes and reaffirm Zenas BioPharma’s commitment to innovative health solutions.
Contact Information
For investors and media inquiries, please reach out to Argot Partners. Direct your queries via email to Zenas@argotpartners.com for more information on the company’s recent developments and strategic vision.
Frequently Asked Questions
What is Zenas BioPharma known for?
Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune diseases.
When and where will Zenas present?
Zenas will present at the Jefferies Global Healthcare Conference on November 18 and the Evercore Healthcare Conference on December 3.
How can I access their presentations?
Live webcasts and archived replays will be available on the Zenas BioPharma website under the 'Events and Presentations' section.
What are Zenas' lead product candidates?
The lead product candidates include obexelimab and orelabrutinib, both of which are undergoing late-stage development.
Who can be contacted for more information?
Inquiries can be sent to Argot Partners at Zenas@argotpartners.com for investor-related questions.
